FOLH1 and prostate carcinoma: To evaluate eligibility for PSMA-targeted RLT, the following information should be reported: (1) overall visual uptake intensity of prostate cancer lesions in reference to liver ([68 Ga]Ga-PSMA-11, [68 Ga]Ga-PSMA-I&T, [18F]F-DCFPyL, [18F]F-rhPSMA-7.3) or spleen ([18F]F-PSMA-1007).